A randomised controlled trial of Tranexamic acid in Intracerebral Haemorrhage (TICH) - Tranexamic acid in Intracerebral Haemorrhage (TICH)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-022009-16-GB

Enrollment

Registered

2010-08-27

Start date

2010-11-01

Completion date

Unknown

Last updated

2013-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary intracerebral haemorrhage

Interventions

Trade Name: Cyklokapron Product Name: Tranexamic acid CYKLOKAPRON INJECTION (500mg in 5ml) Pharmaceutical Form: Injection*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients with primary intracerebral haemorrhage confirmed on CT brain Event =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: • Secondary haemorrhagic stroke (anticoagulation, known vascular malformations) • Previous venous thrombo-embolic disease • Recent (within 12 months) ischaemic events (ischaemic stroke, myocardial infarction, peripheral artery disease) • Renal impairment (eGRF <50mmols) • Pregnancy or breast feeding • Patients who are pregnant or breast feeding

Design outcomes

Primary

Measure	Time frame
Main Objective: Primary: To test the feasibility, tolerability and acceptability (adverse events) of tranexamic acid in haemorrhagic stroke (bleeding in to the brain). ;Secondary Objective: Secondary: To test the effects of tranexamic acid on haematoma expansion (growth in the size of blood clot) and death and dependency in haemorrhagic stroke (bleeding in to the brain).;Primary end point(s): Feasibility - number of enrolled patients receiving allocated treatment	—

Measure

Time frame

Main Objective: Primary: To test the feasibility, tolerability and acceptability (adverse events) of tranexamic acid in haemorrhagic stroke (bleeding in to the brain). ;Secondary Objective: Secondary: To test the effects of tranexamic acid on haematoma expansion (growth in the size of blood clot) and death and dependency in haemorrhagic stroke (bleeding in to the brain).;Primary end point(s): Feasibility - number of enrolled patients receiving allocated treatment

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026